SCHEMBL979826

SCHEMBL979826

CS(=O)(=O)O.CS(=O)(=O)Oc1ccc(CC(=O)O)cc1

nearest known ligand 0.51

Known targets — ChEMBL curated mechanism

ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol

The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KLK1 P06870 1/20 0.51
PRSS1 P07477 1/20 0.51
KDM4E B2RXH2 1/20 0.50
POLB P06746 1/20 0.50
CA5A P35218 1/20 0.48
PTGS1 P23219 2/20 0.46
AKR1C3 P42330 1/20 0.46
AKR1C2 P52895 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
CA2 P00918 1/20 0.46
CAMK2A Q9UQM7 1/20 0.46
SRD5A2 P31213 2/20 0.45
PPARA Q07869 4/20 0.44
PPARG P37231 3/20 0.44
AKR1B1 P15121 1/20 0.44
ALDH1A1 P00352 1/20 0.43
HPGD P15428 1/20 0.43
HSD17B10 Q99714 1/20 0.43
ABCC4 O15439 1/20 0.43
LMNA P02545 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL979293 0.96 KDM4E (0.49) KLK1PRSS1KDM4EPOLBCA5A
SCHEMBL7898011 0.84 CA5A (0.55) KLK1PRSS1KDM4EPOLBCA5A
SCHEMBL980066 0.83 CYP4F2 (0.54) PPARAPPARGALDH1A1GAAHTT
SCHEMBL10766654 0.81 PPARA (0.42) POLBPPARAPPARGALDH1A1HTT
SCHEMBL4074491 0.79 FFAR1 (0.57) L3MBTL1CA2SRD5A2PPARAPPARG
SCHEMBL24692740 0.79 CA2 (0.48) KLK1PRSS1KDM4EPOLBCA5A
Phenylacetic Acid SCHEMBL23925805 0.77 AKR1B1 (0.74) KDM4EPOLBPTGS1CA2CAMK2A
SCHEMBL4461203 0.77 CA2 (0.47) KDM4EPOLBCA5APTGS1AKR1C3
SCHEMBL31497792 0.77 MMP2 (0.41) KDM4ECA2PPARAPPARGALDH1A1
SCHEMBL978183 0.76 PPARA (0.46) KDM4ECA5ACA2PPARAPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110166157-A1 2-Substituted-3-Phenylpropionic Acid Derivatives and Their Use in the Treatment of Inflammatory Bowel Disease ALBIREO AB (SE) 2011-07-07 US disclosed
US-20110021534-A1 2 -SUBSTITUTED- 3 -PHENYLPROPIONIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE ALBIREO AB (SE) 2011-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110021534-A1 2 -SUBSTITUTED- 3 -PHENYLPROPIONIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE TPMT, FABP2, PTGES2 KLK1 4739/4885PRSS1 774/4885KDM4E 841/4885
US-20110166157-A1 2-Substituted-3-Phenylpropionic Acid Derivatives and Their Use in the Treatment of Inflammatory Bowel Disease TPMT, FABP2, PTGES3 KLK1 4727/4885PRSS1 755/4885KDM4E 1332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.